

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Riou et al.

Examiner: **Melissa Jean Perreira**

Art Unit: **1618**

Application No.: **10/644,411**

Filed: **August 20, 2003**

Title: **Oxindoles Which Are Inhibitors of CDK-1 and Their Application in
Therapeutics**

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith a list of patents, publications, and other information, and copies thereof as required by 37 C.F.R. 1.98, of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

Further to 37 C.F.R. 1.98(a)(2)(ii), no copy of any listed U.S. patent or publication is provided herewith.


As a convenience to the Examiner, Applicants respectfully point out the following:

U.S. Patent Nos. 6,316,429 and 6,133,305 were cited by the Examiner on PTO Form 892 in the Examiner's Office Action mailed July 26, 2006. These patents are in the same patent family as listed reference WO 98 50356.

U.S. Patent No. 5,792,783, was also cited by the Examiner on PTO Form 892 in the Examiner's Office Action mailed July 26, 2006. This patent is in the same patent family as listed reference WO 96 40116.

This Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311.

The Commissioner is hereby authorized to charge the fee, pursuant to 37 C.F.R. 1.97(c) and 37 C.F.R. 1.17(p), of \$180.00, to Deposit Account 18-1982, upon which the undersigned is authorized to draw. The Commissioner is hereby authorized to charge any underpayment, or credit any overpayment to Deposit Account 18-1982.

<p>Date <u>January 18, 2007</u></p>	<p>Respectfully submitted,  _____ Paul R. Darkes Reg. No. 33,862 Attorney for Applicants</p>
-------------------------------------	--

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone 610-889-8458
Telefax 908 231-2626
sanofi-aventis Docket No. ST01004 US CIP

☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/644,411
				Filing Date	08-20-2003
				First Named Inventor	RIOU
				Group Art Unit	1618
				Examiner Name	PERREIRA, Melissa Jean
Sheet	1	of	2	Attorney Docket Number	ST01004 - US - CIP

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/644,411	
			Filing Date	08-20-2003	
			First Named Inventor	RIOU	
			Group Art Unit	1618	
			Examiner Name	PERREIRA, Melissa Jean	
Sheet	2	of	2	Attorney Docket Number	ST01004 - US - CIP

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

+